Alyeska Investment Group L.P. Invests $5.45 Million in Dyne Therapeutics, Inc. $DYN

Key Points

• Alyeska Investment Group acquired 245,278 shares of Dyne Therapeutics valued at approximately $5.45 million, while institutional investors collectively owned 96.68% of the company.
• Analyst sentiment remains positive overall, with a consensus “Moderate Buy” rating and an average price target of $34.42, despite differing targets ranging from $24 to $50.
• Dyne shares opened at $25.10, near their 12-month high, but the company missed quarterly EPS expectations. Insiders sold roughly 4.14 million shares worth $99.45 million over the past 90 days, including a major 2.16 million-share sale by a director.

Alyeska Investment Group L.P. acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 245,278 shares of the company's stock, valued at approximately $5,448,000. Alyeska Investment Group L.P. owned about 0.13% of Dyne Therapeutics at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. AQR Capital Management LLC purchased a new position in Dyne Therapeutics during the 1st quarter worth $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Dyne Therapeutics by 5.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company's stock worth $597,000 after acquiring an additional 2,886 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company's stock worth $10,407,000 after purchasing an additional 366,183 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of Dyne Therapeutics in the 1st quarter valued at $157,000. Finally, Creative Planning raised its stake in shares of Dyne Therapeutics by 23.8% in the second quarter. Creative Planning now owns 14,541 shares of the company's stock worth $138,000 after purchasing an additional 2,797 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the company. HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Monday, August 17th. Sanford C. Bernstein raised their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a "market perform" rating in a research report on Wednesday, May 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Royal Bank Of Canada increased their price objective on Dyne Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a report on Thursday, July 30th. Finally, Morgan Stanley reduced their target price on Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $34.42.

Dyne Therapeutics Trading Down 1.3%

NASDAQ DYN opened at $25.10 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The company has a market cap of $4.69 billion, a P/E ratio of -7.54 and a beta of 1.08. Dyne Therapeutics, Inc. has a 12 month low of $11.92 and a 12 month high of $27.31. The company has a 50-day moving average of $24.55 and a 200-day moving average of $20.20.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 2,160,516 shares of the company's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the sale, the director owned 428,946 shares of the company's stock, valued at $10,723,650. This represents a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of the company's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the sale, the chief financial officer owned 121,563 shares of the company's stock, valued at approximately $2,476,238.31. This trade represents a 1.91% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 4,139,196 shares of company stock worth $99,449,852. Insiders own 9.46% of the company's stock.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source